Table 1 Association of PinX1 expression with patientās clinicopathological features in NSCLC
Variable | Learning cohort | Validation cohort | ||||||
|---|---|---|---|---|---|---|---|---|
Cases | Negative expression (%) | Positive expression (%) | P-value* | Cases | Negative expression (%) | Positive expression (%) | P-value* | |
Age(years) | ||||||||
ā<56a | 42 | 21(50%) | 21(50%) | 0.068 | 22 | 13(59.1%) | 9(40.9%) | 0.443 |
āā„56a | 51 | 35(68.6%) | 16(31.4%) | 29 | 14(48.3%) | 15(51.7%) | ||
Gender | ||||||||
āMale | 61 | 39(63.9%) | 22(36.1%) | 0.312 | 35 | 17(48.6%) | 18(51.4%) | 0.355 |
āFemale | 32 | 17(53.1) | 15(46.9%) | 16 | 10(62.5) | 6(37.5%) | ||
Smoking Condition | ||||||||
āSmoker | 42 | 32(76.2%) | 10(23.8%) | 0.004 | 20 | 16(80%) | 4(20%) | 0.002 |
āNonsmoker | 51 | 24(47.1%) | 27(52.9%) | 31 | 11(35.5%) | 20(64.5%) | ||
WHO grade | ||||||||
āG1 | 28 | 18(64.3%) | 10(35.7%) | 0.708 | 16 | 9(56.2%) | 7(43.8%) | 0.843 |
āG2 | 37 | 22(62.2%) | 15(37.8%) | 20 | 11(55%) | 9(45%) | ||
āG3 | 28 | 16(57.1%) | 12(42.9%) | 15 | 7(46.7%) | 8(53.3%) | ||
Histological Type | ||||||||
āSquamous cell carcinoma | 37 | 29(78.4%) | 8(21.6%) | 0.002 | 22 | 16(72.7%) | 6(27.3%) | 0.046 |
āAdenocarcinoma | 46 | 25(54.3%) | 21(45.7%) | 23 | 9(39.1%) | 14(60.9%) | ||
āOthers | 10 | 2(25%) | 8(75%) | 6 | 2(33.3%) | 4(77.7%) | ||
T stage | ||||||||
āT1-T2 | 38 | 15(39.5%) | 23(60.5%) | 0.001 | 18 | 4(22.2%) | 14(88.8%) | 0.001 |
āT3-T4 | 55 | 41(74.5%) | 14(25.5%) | 33 | 23(69.7%) | 10(30.3%) | ||
N stage | ||||||||
āN0 | 26 | 9(34.6%) | 15(57.7%) | 0.005 | 16 | 5(31.2%) | 11(68.8%) | 0.036 |
āN1-N3 | 67 | 47(70.1%) | 22(29.9%) | 35 | 22(62.9%) | 13(37.1%) | ||
M stage | ||||||||
āM0 | 66 | 45(68.2%) | 21(31.8%) | 0.014 | 35 | 14(40%) | 21(60%) | 0.006 |
āM1 | 27 | 11(40.7%) | 16(59.3%) | 16 | 13(81.2%) | 3(18.8%) | ||
TNM stage | ||||||||
āI-II | 25 | 6(24%) | 19(76%) | 0.000 | 14 | 4(28.6%) | 10(71.4%) | 0.032 |
āIII-IV | 68 | 50(73.5%) | 18(26.5%) | 37 | 23(62.2%) | 14(37.8%) | ||